Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease

Abstract Background The multiple disease domains affected in psoriatic arthritis (PsA) may make composite endpoints appropriate for assessing changes in disease activity over time. Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Data from two phase 3 studies of patients with...

Full description

Bibliographic Details
Main Authors: Philip Helliwell, Laura C. Coates, Oliver FitzGerald, Peter Nash, Enrique R. Soriano, M. Elaine Husni, Ming-Ann Hsu, Keith S. Kanik, Thijs Hendrikx, Joseph Wu, Elizabeth Kudlacz
Format: Article
Language:English
Published: BMC 2018-10-01
Series:Arthritis Research & Therapy
Subjects:
Psoriatic arthritis
Assessment
PASDAS
DAPSA
CPDAI
DAS28–3(CRP)
Online Access:http://link.springer.com/article/10.1186/s13075-018-1739-0

Internet

http://link.springer.com/article/10.1186/s13075-018-1739-0

Similar Items